Vol.70 No.6 November 2022
Administration of the neutralizing antibody sotrovimab to 24 patients with COVID-19 at a long-term care facility
1)Department of Rheumatic Disaeses, Tokyo Metropolitan Tama-Hokubu Medical Center, 1-7-1 Aoba, Higashimurayama, Tokyo, Japan
2)Nursing Department, Tokyo Metropolitan Tama-Hokubu Medical Center
3)Department of Internal Medicine, Tokyo Metropolitan Tama-Hokubu Medical Center
4)Vice President, Tokyo Metropolitan Tama-Hokubu Medical Center
Abstract
Large clusters of patients with COVID-19 can occur at long-term care facilities. The very high care demand of these patients makes it difficult to treat all cases as inpatients. We provided guidance for infection control and administrated the neutralizing antibody sotrovimab to 24 patients with COVID-19 to stop the spread of the infection during our visit to a facility with a large COVID-19 cluster. Treatment interventions by institutional visits have the advantages of controlling exacerbation, preventing further spread of the infection, and conserving medical resources at hospitals. We believe it is worthwhile considering this strategy for COVID-19 clusters at long-term care facilities.
Key word
COVID-19, long-term care facility, neutralizing antibody, sotrovimab
Received
March 23, 2022
Accepted
July 21, 2022
Jpn. J. Chemother. 70 (6): 453-459, 2022
